{
    "clinical_study": {
        "@rank": "18411", 
        "arm_group": [
            {
                "arm_group_label": "BEV plus", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel  175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1\u300115; 28 days a cycle"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Paclitaxel  175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment\n      for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study\n      in patients with previously untreated metastatic mucosal melanoma to characterize the\n      efficacy and safety of bevacizumab when combined with carboplatin plus paclitaxel."
        }, 
        "brief_title": "Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Mucosal melanoma is rare and associated with extremely poor prognosis.It is the second most\n      common subtype in Asians.No effective treatment for advanced mucosal melanoma\n      patients.Malignant melanoma is a highly vascular tumor in which vascular endothelial growth\n      factor(VEGF) is strongly expressed and seems to play an important role in disease\n      progression.A randomized phase II study evaluated the activity of Bevacizumab in combination\n      with carboplatin plus paclitaxel(CPB arm) in patients with previously untreated advanced\n      melanoma.Overall response rates was 25.5%,median overall survival time(OS) was 12.3 months\n      in the CPB arm. Investigators conducted a randomized phase II study in patients with\n      previously untreated metastatic mucosal melanoma to characterize the efficacy and safety of\n      bevacizumab when combined with carboplatin plus paclitaxel."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed mucosal melanoma with metastases and has no received any\n             systemic treatment.\n\n          2. ECOG performance status 0, 1\n\n          3. Estimated life expectancy of 12 weeks or greater\n\n          4. Age 18 years or older, male or female\n\n          5. At least one measurable site (diameter\u22651cm) of disease (RECIST 1.1).\n\n          6. Adequate organ function\n\n          7. Without symptoms of brain metastases and stable in neuro-functions.\n\n          8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures\n\n        Exclusion Criteria:\n\n          1. Mutations in C-KIT or BRAF-V600E, asked for other target treatments\n\n          2. Pregnant or lactation women\n\n          3. Acute infections without control.\n\n          4. Heart disease history, cardiac function class\u2265NYHA II.\n\n          5. HIV positive or chronic HBV/HCV in active stage.\n\n          6. Brain metastases or primary tumor with positive symptoms\n\n          7. Need anti-epileptic treatments\n\n          8. Organ transplantation history\n\n          9. Hemorrhagic tendency or related history\n\n         10. Renal dialysis patients\n\n         11. Diagnosis of any second malignancy within the last 3 years, except for adequately\n             treated.\n\n         12. Current treatment on another clinical trial\n\n         13. The other improper situations which investigator judged."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "182", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023710", 
            "org_study_id": "BCH-MM-131101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BEV plus", 
                    "Control"
                ], 
                "description": "175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxel"
            }, 
            {
                "arm_group_label": [
                    "BEV plus", 
                    "Control"
                ], 
                "description": "Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "CBP"
            }, 
            {
                "arm_group_label": "BEV plus", 
                "description": "5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "BEV"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mucosal melanoma", 
            "Bevacizumab", 
            "Carboplatin", 
            "Paclitaxel"
        ], 
        "lastchanged_date": "December 24, 2013", 
        "location": [
            {
                "contact": {
                    "email": "zxs617@hotmail.com", 
                    "last_name": "Xiaoshi Zhang, MD", 
                    "phone": "0086-20-87343088"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510060"
                    }, 
                    "name": "Sun Yat-sen University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Xiaoshi Zhang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "doctor_sheng@126.com", 
                    "last_name": "Xinan Sheng, MD", 
                    "phone": "0086-10-88196951"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }, 
                    "name": "Beijing Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Jun Guo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "songxin68@126.com", 
                    "last_name": "Xin Song, MD", 
                    "phone": "0086-871-8185656"
                }, 
                "facility": {
                    "address": {
                        "city": "Kunming", 
                        "country": "China", 
                        "zip": "650106"
                    }, 
                    "name": "Yunan Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Xin Song, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma", 
        "overall_contact": {
            "email": "doctor_sheng@126.com", 
            "last_name": "Xinan Sheng, MD", 
            "phone": "0086-10-88196951"
        }, 
        "overall_official": {
            "affiliation": "Beijing Cancer Hospital", 
            "last_name": "Jun Guo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause.", 
            "measure": "progress-free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "From randomization up to 144 weeks"
        }, 
        "reference": [
            {
                "PMID": "22124101", 
                "citation": "Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28."
            }, 
            {
                "PMID": "21349197", 
                "citation": "Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011 Feb 25;11:85. doi: 10.1186/1471-2407-11-85."
            }, 
            {
                "PMID": "23833309", 
                "citation": "Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, Li S, Kong Y, Tang B, Guo J. Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013 Aug 15;19(16):4488-98. doi: 10.1158/1078-0432.CCR-13-0739. Epub 2013 Jul 5."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023710"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing Cancer Hospital", 
            "investigator_full_name": "Jun Guo", 
            "investigator_title": "Director of department of renal cancer and melanoma", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Any events,no matter related to interventions,occur during the period from the enrollment to death or 30 days after withdrawal from the trial", 
                "measure": "adverse event(AE)", 
                "safety_issue": "Yes", 
                "time_frame": "From randomization up to144 weeks"
            }, 
            {
                "description": "Overall survival was defined as the time from randomization to death from any cause.", 
                "measure": "Overall Survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 144 weeks"
            }
        ], 
        "source": "Beijing Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}